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Atherosclerosis and Antioxidants
Yehoshua Lewis

Abstract:
Cellular lipid oxidation is a known cause for the cascade leading to the formation of lipid laden
foam cells, which can cause of atherosclerosis. While statins and antioxidants have recently
come under question in the amelioration of atherosclerosis, Flavonoids have recently been
touted as a powerful antioxidant and suppresser of atherosclerosis. This paper will attempt to
show why statins and vitamin E have come under scrutiny, and how the desired effects of
Flavonoids can be attributed to the role it plays in increased paraoxonase-1 activity (a known
anti inflammatory associated with HDL), decreased C- Reactive protein activity, and increased
nitric oxide (NO) in endothelial cells among other factors.
Introduction:
Coronary artery disease (CAD) is the leading cause of death in the United States every year. According to
the Center for Disease Control and the National Center for Health Statistics, data for the year 2004
indicate that heart disease killed 652,486 people (U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES,
2008). This is nearly 100,000 more than the second leading cause of death in the United States, cancer.
Atherosclerotic plaque build-up in the arteries is the cause of CAD, and has been the primary focus of
scientists in search of a cure for CAD. Needless to say, much research has been done on finding the
causes of heart disease and developing drugs that inhibit its development. Other then pharmacological
products, there is a very large body of research into more natural remedies for atherosclerosis, including
antioxidants such as vitamin E that have been touted as providing protection against lipid oxidation.
Recently, however, there is a growing body of evidence that statins and antioxidant supplementation
may not be beneficial as thought. In contrast, Flavonoids, by operating under mechanisms different then
antioxidants and statins, offers new hope in the treatment of atherosclerosis.

Coronary Artery Disease:
While there are many factors that contribute to CAD, there are a number of factors specifically related
to atherosclerosis that play a key role in its development. Atherosclerosis is a progressive disease of the
arteries and is the result of plaque buildup in the arteries driven by the
uptake of cholesterol in artery walls (Medline Plus, 2007). Lipids are not
water soluble, and must rely on lipoproteins, produced in the liver and
small intestines, in order to be transported in the blood. By combining
lipids with lipoproteins, the lipids are able to be transported either to the
liver for elimination, or from the liver for the production of steroid
Figure 1. Dissected aorta with
hormones, bile salts, and for cell membrane repair. The two major
atherosclerotic lesions (Ewing,
lipoproteins involved in these functions are low-density lipoproteins
1972)
(LDL), and high-density lipoprotein (HDL); with LDL being responsible
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lipid transport from the liver, and HDL being responsible for transport of lipids to the liver for
elimination (Tortora & Derrickson, 2006).
Plaque formation begins with the aggregation of excess LDL in the inner layer of arterial walls
where the lipoproteins are subject to oxidation. In response, substances released by endothelial and
smooth muscle cells attract macrophages that ingest the oxidized LDL forming plaque. So much so, that
the macrophages take on a foamy appearance under the microscope (foam cells). Additionally,
lymphocytes (T cells) follow the macrophages into the arterial wall and increase the streaks in the
arterial walls. Subsequently, the macrophages cause the migration of the middle layer of the artery to
the surface of the plaque thus separating it from the bloodstream, but also narrowing the arterial
lumen. In the event that the cap over the plaque bursts, the T cells stimulate the foam cells to produce
tissue factor (TF), which ultimately leads to blood clot formation and possible obstruction of the
coronary artery, resulting in myocardial infarction (MI). Other factors currently being considered by
researchers include C-reactive proteins, which bind to damaged cells and assist in phagocytosis, clotting
factors, and the amino acid homocysteine that promotes platelet aggregation (Tortora & Derrickson,
2006).

Statins:
In order to treat atherosclerosis,
scientists have focused their attention on
reducing the amount of cholesterol
available in the bloodstream for oxidation
with the use of statin drugs.
In the 1960’s (Endo, 1992) scientists
discovered that when cholesterol is
completely eliminated from the diet, the
liver takes over and produces up to 82%
percent of the required cholesterol.
However, when cholesterol is added to the
diet the synthesis of cholesterol is almost
completely suppressed. They discovered
that the production or suppression of
cholesterol was in response to modulation
by HMG-CoA reductase which modulates
the inhibition of the Mevalonate pathway
of cholesterol synthesis (Figure 2). Through
modulating this enzyme they were able to
Figure 2. Mevalonate pathway of cholesterol synthesis
alter the production of cholesterol. Thus
(Chemistry Daily, 2007)
was born the first statin drugs. However,
there
are medical researchers who challenge the claim that statin drugs actually lower the risk factors for
myocardial infarction (MI). In a scathing review of studies purporting to show that by lowering
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cholesterol with statin drugs mortality rates are decreased, Kauffman (Kauffman, 2007) cites a study
carried out in New York City of a group of 2,277 people with the median age of 76 who were studied for
a period of ten years. What he found was that “The chance of dying was twice as great in subjects with
the lowest quartile of total cholesterol (TC) or LDL-C levels, compared with those in the highest
quartile”. Kauffman goes on to cite another study which shows that for men aged 35-57 “all cause”
mortality rates increased for those with a TC of <170 mg/dL and the risk increased further as TC
decreased to <140 mg/dL to the same levels seen for subjects with extremely high cholesterol
>300mg/dL. Kaufmann flatly states “Serum TC level is not even predictive of cardiovascular disease
(CVD) in men over the age of 47”. Kauffman is not alone in challenging the use of statins; the British
Medical Journal (Ravnskov et al., 2006) also challenges its widespread use, safety and efficacy. This
raises serious questions about how the medical community is facing the challenge of CAD.

Oxidation:
While statins focus on reducing TC as a remedy to the formation of atherosclerosis, there is
another very important juncture in the formation of atherosclerosis that has been the focus of research,
namely oxidative stress caused by free radicals and reactive oxygen species (ROS). ROS and free radicals
are injurious to lipids, DNA, and proteins if left unchecked by the bodies’ native defense mechanisms
(Davis, 1995). What are ROS and free radicals and why are they so important?
Examples of ROS include hydrogen peroxide (H2O2), hypochlorous acid (HClO). Free radicals
include superoxide anion (·O2−) and hydroxyl radical (·OH) (Davis, 1995). One source of the free radical
superoxide anion (·O2−) is that produced by the NADH/NADPH oxidase in macrophages during the
uptake of LDL (Runge, 1999). The superoxide is formed during the electron transport chain (ETS) when
the reduction of coenzyme Q in complex III forms the unstable Q·− radical which can leak electrons
directly to oxygen instead of cascading down the rest of the ETS thus forming superoxide radicals
(Holbrook, 2000).
Considering that 1% - 15% of O2 respired by mammals undergoes the superoxide anion (·O2−)
state (McGraw-Hill's Access Science), there is also ample opportunity to form undesired side reactions.
An example of a side reaction causing oxidative stress results when superoxide reacts with nitric oxide
(NO) to form peroxynitrite (·O2− + ·NO → ONO2−). Peroxynitrite then reacts as a strong oxidizing agent
with lipids, DNA, and proteins. Superoxide and NO individually can both be efficiently removed from the
body. Superoxide reacts with hydrogen in the presence superoxide dismutase (SOD) to form oxygen and
hydrogen peroxide (2·O2− + 2H+ → O2 + H2O2), which can then be converted by catalase to water and
oxygen. NO is rapidly removed by its diffusion through tissues into red blood cells. However, when
compared with SOD, the kinetics and thermodynamics during a reaction of NO and superoxide favor the
formation of peroxynitrite - resulting in the inevitable formation of a highly reactive oxidizing agent.
Peroxynitrite acts as a potent oxidizing agent towards LDL which then becomes the target for scavenger
cells and the formation of foam cells. Various studies have also shown that LDL can be oxidized by
peroxynitrite even in the presence of endogenous lipophilic antioxidants (Pacher et al., 2007).
Another source of oxidation is the Hydroxyl radicals (•OH) that are produced in the iron
catalyzed Haber-Weiss reaction. The Haber-Weiss reaction (Koppenol, 2001) was first discovered in the
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early 1930’s by Fritz Haber and Josef Weiss and proceeds as follows: Recalling that 1%-15% of O2
respired by mammals undergoes the superoxide anion (·O2−) state, we can propose the following
reactions:
Fe3+ + •O2− → Fe2+ + O2,
Followed by the Fenton reaction:
Fe2+ + H2O2 → Fe3+ + OH− + •OH,
For a net reaction of:
•O2- + H2O2 → •OH + HO- + O2.
Hydroxyl radicals are short lived in vivo, (Approx 10-9 s) and are highly reactive (Yan et al., 2005).
They also cannot be enzymatically removed because of its short half life and tends to react extremely
quickly with whatever is in its vicinity including: carbohydrates, nucleic acids, lipids, and amino acids.
The limitations of this process are inherent in that it requires Iron III in order to proceed, and the
blood plasma protein Transferrin is very effective at scavenging free iron, making it unavailable for
reduction. However, if there is a buildup of iron either due to dietary Iron overload or any other multiple
of diseases, it can outstrip the ability of Transferrin to perform properly and results in the production of
free radicals (Fouad, 2008).

Antioxidants:
As the oxidation of lipids form a key step in the formation of atherosclerosis, it should also lead
to the conclusion that “antioxidants” offer protection against lipid oxidation. However, the more
research that is being done, the more it becomes clear that exogenous sources of antioxidants have
questionable effects in vivo. The field of antioxidants is very broad and can be the subject of many
papers, but just to scratch the surface; antioxidants can be broken down into metabolite and enzymatic
categories as well as lipid soluble and water soluble. The difference between them is their mechanism as
well as site of action. For example: lipid soluble antioxidants act in cell membranes, and water soluble
antioxidants act in the blood plasma and cytoplasm. Lipid soluble antioxidants include vitamin E and
coenzyme Q (Q10). Water soluble antioxidants include ascorbic acid (vitamin C), glutathione, lipoic acid,
uric acid, and polyphenols (Flavonoids, tannins). Enzymatic antioxidants include the previously
mentioned SOD, catalase, as well as glutathione among others (Sies, 1997).
Vitamin E is a potent antioxidant and some research has shown that it can regulate HMG-CoA
reductase (Pal et al., 2003; Parker, 1993). Vitamin E is the name for a group of four tocopherols and four
tocotrienols, of which the most interesting to scientists is the α-tocopherol variety because of its high
bioavailability. Vitamin E is the main lipid-soluble antioxidant in the body and it works in cell membranes
where it prevents the propagation of free radical reactions (Herrera & Barbas, 2001).
Because vitamin E is lipid soluble, when absorbed vitamin E is packaged in Chylomicrons (large
lipoprotein particles) that are produced in the absorptive cells in the small intestine. They are then
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secreted via exocytosis into lacteals of the lymphatic system and delivered into the circulatory system at
the juncture of the thoracic duct and the left subclavian where they are transported to the liver. At the
liver, lipoprotein lipase (LPL) induces the unloading of some of the chylomicrons into the extrahepatic
tissue and the remainder chylomicrons transports the tocopherols into the liver. Here, “α-tocopherol
transfer protein" incorporates α-tocopherol into very low density lipoprotein (VLDL) the excess of which
is excreted into the bile duct. The α-tocopherol binded VLDL is then transported into circulation where it
is converted to LDL again by the action of LPL. The α-tocopherol is then taken up by the endothelial cell
membrane by the uptake of LDL via cell receptors (Herrera & Barbas, 2001).
Once in the cell membrane, α-tocopherol can act as a terminator to lipoprotein oxidation chain
reaction as follows:
Where “I” is the initiator and “LH” is the fatty
and L• is formed from the fatty acid

acid

I + LH → L• + IH [1]
Propagation continues as follows:
L• + O2 → LOO• [2]
LOO• + LH → LOOH + L• [3]
(See Figure 3)
Termination occurs when tocopherol “TO”
breaks the chain reaction:
LOO• + TOH → LOOH + TO• [4]
The tocopheroxyl radical then reacts with
another peroxyl radical to form tocopheryl
quinine (Q10) and thereby arresting the chain
reaction (Wolf, 2005).

Figure 3. The free radical mechanism of lipid
peroxidation

As with almost every system in the body, vitamin E does not function in isolation but is part of an
antioxidant network in which vitamin E can be synthesized from vitamin C and thiol redox cycles
involving glutathione and lipoic acid. (See attachment). Vitamin C has pro-oxidant properties as well
because of its ability to reduce metal ions via the Fenton reaction which can be a source of oxidative
stress. However, this is thought to be of minor significance as compared with its antioxidant properties
(FREI, 1999).
On the other front, research has shown that vitamin E, specifically tocotrienols, can modulate HMG-CoA
reductase similar way to that done by statins as discussed previously. (Parker et al., 1993)
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A number of studies showed this effect in mammals. In one study hyperlipidemic pigs given a
diet rich in tocotrienols showed a marked decrease in plasma concentrations of cholesterol,
apolipoprotein B (required in the formation of LDL), thromboxane B2 and platelet factor 4(both required
for blood coagulation), indicating a protective effect on endothelium and platelet aggregation (Qureshi
et al., 1991). There have been some conflicting results in similar trials in humans; however, those may
be attributed to plasma levels of tocotrienols and not to the efficacy of the compound (Packer et al.,
2001). It would thus seem that by ingesting vitamin E one would be able to take concrete measures in
arresting the propagation of atherosclerosis.
However, a recent Meta analysis by The Cochrane Collaboration - of studies proving the
remedial effects of vitamin E as well as other antioxidants - has not supported those results. Not only did
the ingestion of exogenous antioxidants not prove to be beneficial but has also shown to be detrimental.
The study included 232,550 participants who were “randomised to antioxidant supplements (betacarotene, vitamin A, vitamin C, vitamin E, and selenium) versus placebo or no intervention”. “A total of
17,880 of 136,023 participants (13.1%) randomised to antioxidant supplements and 10,136 of 96,527
participants (10.5%) randomised to placebo or no intervention died. In the analyses of the trials with low
risk of bias, beta-carotene, vitamin A, and vitamin E significantly increased mortality.” The study flatly
states that there is no evidence to support antioxidant supplementation. This study brings into question
the widespread use of antioxidants as a remedial and/or prophylactic compound for oxidative diseases
(Bjelakovic et al., 2008).

Flavonoids:
Increased consumption of fruits and vegetables is associated with reduced incidences of CAD
and other disease. The cause of this has been attributed in part, to antioxidant Flavonoids present in
these foods. The hypothesis in this case is that because after the consumption of Flavonoids there is a
marked increase in the antioxidant properties of blood plasma and it can play a direct role in the
prevention of lipid oxidation (Lotitoa & Frei, 2006). A clear example of this can be seen in the French
paradox, where despite the French consuming large amounts of red meat that are rich in unsaturated
fats they still develop lower instances of death from CAD then Americans. This has been attributed to
their consumption of red wine which is rich in Flavonoids (Ferrières, 2004).
Michael Aviram of the Technion faculty of medicine has done extensive research in the field of
pomegranate polyphenols (Flavonoids), and has made a very important contribution to the field. Among
the points studied three will be focused on: Antioxidant properties of blood plasma, paraoxonase-1
(PON-1)1 levels, and aortic stenosis - all after the ingestion of PJ. In one study (Aviram, et al., 2000), both
healthy human males and atherosclerotic E-deficient (E0) mouse subjects were fed PJ for variable
periods of time. The objective of the study was to determine what effect PJ consumption had on
lipoprotein oxidation, aggregation and retention; macrophage atherogenicity; platelet aggregation; and
atherosclerosis. The results of the study were striking. In humans, PJ consumption resulted in a decrease
in LDL susceptibility to aggregation (-11% ex vivo) and retention, also observed was serum PON-1
increased activity by 20% and that it also had a protective effect against LDL oxidation. Human plasma in
1

Paraoxonase1 (PON1) is an anti-inflammatory enzyme located on HDL.
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one case showed a decrease in lipid plasma peroxidation of ≤33%. In E0 mice, a 90% decrease in LDL
oxidation was observed as well as a 20% decrease in the uptake of LDL by peritoneal macrophages. Also
observed was a 44% decrease in atherosclerotic lesions and foam cells as compared with water fed
mice. Aviram et al., attributes the protective antioxidant effect of PJ to increased cellular glutathione
content, and states that the reduction of atherosclerotic lesions is directly related to the antioxidant
properties of PJ. Another study by Aviram of the long term effects of PJ consumption - in human
subjects with carotid artery stenosis (CAS) - on carotid lesions and changes in oxidative stress and blood
pressure had remarkable results. After 1 year control subjects showed a 9% increase in intima-media
thickness (IMT) as opposed to the PJ group that showed a 30% decrease in IMT. PON-1 activity increased
by 83%, serum LDL basal oxidative state was reduced by 90%, copper ion induced oxidation was reduced
by 59% and total antioxidant status (TAS) increased by 130%. Again, Aviram attributes these results to
the antioxidant characteristics of PJ polyphenols (Aviram, et al., 2004).
Jane Higdon, Ph.D. of The Linus Pauling Institute at Oregon State University takes a different
tack and claims that because the bioavailability of Flavonoids is very low, its antioxidant properties
cannot be attributed to the antioxidant properties proved in vitro. For example, the bioavailability of
Flavonoids in vivo is 100-1000 times lower than the bioavailability of vitamin C or glutathione and thus
has a very small antioxidant effect. However, it is available in concentrations that effect cell signaling
proteins. “Numerous studies in cell culture suggest that flavonoids may affect chronic disease by
selectively inhibiting kinases” including those related to growth factors. Higdon hypothesizes that it is
this property that protects against CAD by decreasing inflammation, decreasing vascular cell adhesion
molecule expression, increasing endothelial nitric oxide synthase (eNOS) activity, and decreasing
platelet aggregation (Higdon, 2005). Another study (Lotito & Frei, 2006), attributes the protective effect
of Flavonoids not directly to its antioxidant activity, but rather to the consequence of increased uric
acid.2 What is clear from all these studies is that it is not the antioxidant properties of Flavonoids that
directly protect against CAD but rather to a whole host of activities including: increased native
antioxidants such as glutathione, uric acid, modified cell signaling pathways, increased PON-1 activity,
and increased NO levels.

Possible Risks of Antioxidants vs. Flavonoids:
So then what really does account for the differences in Flavonoids and for example vitamin E?
What may be at play is as follows:
Vitamin E as well as having antioxidant properties is a pro-oxidant as well (Bowry et al., 1992).
For example: instead of the termination reaction by tocopherol to the oxidative chain reaction of lipids
as a final step:
LOO• + TOH → LOOH + TO• [4]
We instead form
2

Recent studies have implicated hyperuricemia as being a true risk factor in development of cardiovascular
disease (Jing Fang & Michael H. Alderman, 2000). However, nearly half of the bodies’ antioxidant activity is from
uric acid and in moderation may play a positive role.
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TO• + LH → TOH +L• [5]
This will then feed into the chain reaction
L• + O2 → LOO• [2]
LOO• + LH → LOOH + L• [3]
One study (Bowry, Ingold, & Stocker, 1992) has found that in aqueous solution, strikes between
the stable TO• and other radicals were found to take upward of 17 minutes, a time long enough that
even the most stable radical will find “`something to do’” i.e. propagate the chain reaction. The
termination of this reaction must then rely on two endogenous antioxidants vitamin C, as demonstrated
by the thiol redox cycles (Appendix 1), and ubiquinol (Q10H2, a reduced form of Q10) in the electron
transport chain. What can be inferred from this is that by ingesting vitamin E the body sets off a cascade
of endogenous antioxidants, in order to minimize the damage being incurred by vitamin E. While the
body does have the mechanisms of scavenging TO• how can making more of them by ingesting vitamin
E be advantageous? Essentially there is a delicate balance of electron radicals that are passed down a
cascade until they can be neutralized to a non reactive end product, and by adding more electron
radicals in the form of α-tocopherol it may have the effect of being counterproductive.

C - reactive protein and PON-1
By contrast, Flavonoids are effective not by acting as antioxidants but through modulating the
inflammatory response of oxidized cells.
The relationship between C - reactive protein (CRP) and Flavonoids illustrates this point. CRP is
found to be elevated during inflammatory response by the body, specifically, macrophages and T cells
release Interleukin-6 (IL-6) as a pro inflammatory to stimulate a response to tissue damage. CRP
production is then part of the acute-phase response to most forms of inflammation, infection, and tissue
damage. CRP levels by themselves cannot be used as marker for atherosclerosis, but they have been
positively correlated with CAD (Pepys & Hirschfield, 2003). Flavonoids have an inverse relationship with
CRP. One study using demographic data (Chun et al., 2008) found that the greater consumption of
Flavonoid rich foods, the lower the concentrations of serum CRP thus clearly indicating that Flavonoids
affect inflammatory response. Another study has also found an inverse relationship between levels of
CRP and levels of PON-1 expression. They found that “Higher levels of CRP seem to be generally
associated with low levels of PON1 activity” (Macknessa et al., 2006). Which should lead to the
conclusion that the atherosclerotic protection associated with Flavonoids is not related to an inherent
antioxidant activity but rather to other factors as mentioned.
Another study also found that polyphenols (i.e. Flavonoids) acutely enhanced nitric oxide bioactivity. NO
is necessary to maintain vasodilatation - the lack of which is implicated in increased risk of
cardiovascular disease (Anter et al., 2004).
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Conclusions:
In comparing the protective effects on atherosclerosis associated with statins, vitamin E, and
Flavonoids, there are many questions as to the ability of statins and vitamin E to afford real protection
against atherosclerosis. The data in many cases implicates these very compounds increased mortality
rates. By contrast, Flavonoids have shown themselves able to boost the bodies’ native antioxidants
including uric acid and glutathione, while at the same time reducing the inflammatory response to the
uptake of oxidized lipids. It could be that mother really knew best all along “an apple a day – really does
– keep the doctor away”. (Apple peals have been found to consist of 40% flavonols by weight (Łata &
Tomala, 2007 )).
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